In the news · Newsmax · October 8, 2026
New Glioblastoma Vaccine Sparks Hope
Newsmax features SurVaxM, the investigational immunotherapy MimiVax is developing for glioblastoma.
← Back to News & Resources
Interested in access to SurVaxM? SURVIVE has completed enrollment and no SurVaxM glioblastoma studies are currently enrolling. Patients and caregivers can learn about expanded access, and how to make a request through a treating physician, on the Expanded Access page.
Segment courtesy of Newsmax. SurVaxM is an investigational product. It has not been approved by the FDA or any other regulatory authority. Information on this site is intended for healthcare professionals, researchers and industry partners.